Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the current ratio high or low?
The current ratio of 25.13 is 256% above its 5-year average of 7.05, near the low end of its 5-year range (0.04–90.01).
As of the fiscal period ended Tuesday, June 30, 2026. 169.32% above its 12-month average of 9.33.
Reported quarterly current ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 25.13.
CURRENT RATIO
25.13
CURRENT RATIO AVG TTM
9.33
CURRENT RATIO AVG 3Y
5.14
CURRENT RATIO AVG 5Y
7.05
CURRENT RATIO AVG 10Y
N/A
CURRENT RATIO AVG 15Y
N/A
CURRENT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+169.32%
CURRENT VS 3Y AVG
+389.32%
CURRENT VS 5Y AVG
+256.41%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.75
median of 874 covered companies
CURRENT VS SECTOR MEDIAN
+570.24%
vs the sector median at left
Market Cap
$529.58M
Current Ratio
27.59
TTM Avg
10.29
3Y Avg
10.12
5Y Avg
12.12
Market Cap
$516.76M
Current Ratio
3.46
TTM Avg
4.63
3Y Avg
6.00
5Y Avg
6.13
Market Cap
$533.04M
Current Ratio
33.56
TTM Avg
31.41
3Y Avg
17.80
5Y Avg
16.41
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | $524.43M | 25.13 | 9.33 | 5.14 | 7.05 |
| Shattuck Labs, Inc. (STTK)vs › | $529.58M | 27.59 | 10.29 | 10.12 | 12.12 |
| Altimmune, Inc. (ALT)vs › | $519.25M | 26.78 | 15.83 | 15.06 | 15.09 |
| Nuvectis Pharma, Inc. (NVCT)vs › | $531.52M | 1.68 | 2.23 | 2.63 | 2.59 |
| Delcath Systems, Inc. (DCTH)vs › | $531.98M | 9.83 | 11.46 | 6.57 | 5.79 |
| Aclaris Therapeutics, Inc. (ACRS)vs › | $516.76M | 3.46 | 4.63 | 6.00 | 6.13 |
| Monopar Therapeutics Inc. (MNPR)vs › | $533.04M | 33.56 | 31.41 | 17.80 | 16.41 |
| ProKidney Corp. (PROK)vs › | $538.01M | 8.36 | 10.03 | 20.35 | 14.11 |
| 908 Devices Inc. (MASS)vs › | $505.87M | 2.67 | 4.17 | 6.82 | 10.02 |
| Crescent Biopharma, Inc. (CBIO)vs › | $504.04M | 9.66 | 5.09 | 5.58 | 6.85 |
Current Ratio
25.13
Quick Ratio
25.13
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | CURRENT RATIO |
|---|---|
| 2026-06-30 | 25.13 |
| 2026-03-31 | 8.76 |
| 2025-12-31 | 10.01 |
| 2025-09-30 | 1.53 |
| 2025-06-30 | 1.23 |
| 2025-03-31 | 1.80 |
| 2024-12-31 | 2.33 |
| 2024-09-30 | 3.47 |
| 2024-06-30 | 7.00 |
| 2024-03-31 | 5.82 |
| 2023-12-31 | 5.32 |
| 2023-09-30 | 7.90 |
| 2023-06-30 | 6.47 |
| 2023-03-31 | 8.85 |
| 2022-12-31 | 11.70 |
| 2022-09-30 | 26.90 |
| 2022-06-30 | 19.53 |
| 2022-03-31 | 54.82 |
| 2021-12-31 | 90.01 |
| 2021-09-30 | 0.04 |
| 2021-06-30 | 0.05 |
| 2021-03-31 | 0.00 |
| 2020-12-31 | 0.10 |
| 2020-09-30 | 0.00 |
| 2020-06-30 | 0.00 |
| 2020-03-31 | 0.00 |
